Current portfolio of ca. 20 drugs spans proprietary, in-licensed, and partnered products across several therapeutic areas currently centered around metabolic diseases, oncology and ophthalmology.
Immedica intends to quickly establish full capabilities and further scale across the European and Middle Eastern territories, with a vision to become the leading player in launching niche specialty pharmaceuticals targeting diseases with high unmet medical needs.
Immedica is headquartered in Stockholm, Sweden, and employs c. 40 employees.
